Biohaven Therapeutics Ltd.

This study tests whether a daily pill called BHV-8000 can slow the worsening of motor skills in people recently diagnosed with Parkinson's disease. About 550 adults aged 40 to 85 with early Parkinson's will receive either BHV-8000 (10 mg or 20 mg) or a placebo for up to 48 weeks.…

This study tests whether BHV-1300 can help adults with Graves' disease achieve normal thyroid function without antithyroid drugs. Participants receive either BHV-1300 or a placebo via injection. The main goal is to see if more people on BHV-1300 have normal thyroid hormone levels…

This early study is testing a new drug called BHV-1300 in 15 people with Graves' disease. The main goal is to see if the drug is safe and to check how it affects certain markers of the disease. This is a phase 1 trial, so it's one of the first steps in testing this treatment in h…

This early-stage trial tests a new drug called BHV-1530 in about 95 adults whose solid tumors have spread or cannot be removed. The main goals are to find a safe dose and check for side effects. Researchers will also watch for signs that the drug shrinks tumors or slows the disea…

This early-stage trial tests whether BHV-1400 is safe and tolerable for people with IgA nephropathy, a kidney disease. About 20 participants with confirmed IgA nephropathy will receive the drug subcutaneously. The main goal is to check for side effects and lab abnormalities.

This study tests whether the drug BHV-7000 can safely reduce seizures in adults with focal epilepsy that hasn't improved with other treatments. About 390 participants will receive either the drug or a placebo. The main goal is to see if the drug lowers the number of seizures per …

This early-phase trial is testing a new drug called BHV-1510, either alone or with another drug (cemiplimab), in 500 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and see if the drug can shrink tumors. Because …